BioSpace News Archive

Drug Development

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study

Purple Biotech Ltd. today provided new results from exploratory analyses conducted as part of a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab (NCT04731467).

March 16, 2023
·
8 min read
Business

Saol Therapeutics enhances its IP portfolio for Dichloroacetate (DCA; SL-1009) in Glioblastoma and Rare Pediatric Cancers

Saol Therapeutics announced today the signing of an agreement with Medosome Biotec to provide Saol the rights to use their patented genotype test for all potential indications where SL-1009 might be used as a therapy.

March 16, 2023
·
5 min read
UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated diseases.

March 16, 2023
·
10 min read
Business

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. announced today certain financial and operational results for the fourth quarter and full year ended December 31 , 2022.

March 16, 2023
·
15 min read
Drug Development

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191.

March 16, 2023
·
7 min read
Business

LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

LENSAR, Inc. today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives.

March 16, 2023
·
14 min read
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

Can-Fite BioPharma Ltd. announced today that Dr. Sari Fishman, the Company’s Vice President of Business Development, will participate in the BIO-Europe Spring® partnering conference in Basel, Switzerland from March 20 to 22, 2023.

March 16, 2023
·
5 min read
Business

Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets.

March 16, 2023
·
1 min read
Business

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook

Apyx Medical Corporation today reported financial results for its fourth quarter and full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023.

March 16, 2023
·
17 min read
BioCapital

GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET.

March 16, 2023
·
1 min read